期刊文献+

直接肾素抑制剂阿利吉仑基础和临床研究进展 被引量:1

原文传递
导出
摘要 肾素(renin)是肾素一血管紧张素-醛固酮系统(RAAS)起始和限速的蛋白酶,其作用是切断血管紧张素原第10位亮氨酸与第11位缬氨酸之间的肽键,裂介为10肽血管紧张素Ⅰ(AngⅠ),AngⅠ在血管紧张素转换酶(ACE)作用下,再转化为血管紧张素Ⅱ(AngⅡ)。
作者 张维忠
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2010年第5期478-480,共3页 Chinese Journal of Cardiology
  • 相关文献

参考文献12

  • 1Nguyen G,Delarue F,Burckle C,et al.Pivotal role of the reran/ prorenin receptor in angiotensin Ⅱ production and cellular responses to rennin.J Clin Invest,2002,109:1417-1427.
  • 2Menard J,Cuyene T,Peyrard S,et al.Conformational changes in prorenin during renin inhibition in vitro and in vivo.J Hypertens,2006,24:529-534.
  • 3Brown MJ.Aliskiren.Circulation,2008,118:773-784.
  • 4Wood JM,Maibaum J,Rahuel J,et al.Structure-based design of aliskiren,a novel orally effective renin inhibitor.Biochem Biophys Res Commun,2003,308:698-705.
  • 5Batenburg WW,de Bruin RJ,van Gool JM,et al.Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells.Arterioscler Thromb Vase Biol,2008,26(Suppll):S199.
  • 6Frampton.JE,Curran MP.Aliskiren,a review of its use in the management of hypertension.Drugs,2007,67:1767-1792.
  • 7Gradman AH,Schmieder RE,Lins RL,et al.Aliskiren,a novel orally effective renin inhibitor,provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.Circulation,2005,111:1012-1018.
  • 8Oh BH,Mitchell J,Herron JR.et al.Aliskiren,an oral renin inhibitor,provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.J Am Coll Cardiol,2007,49:1157-1163.
  • 9Oparil S,Yarows SA,Patel S,et al.Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension:randomised double-blind trial.Lancet,2007,370:221-229.
  • 10Lambers Heerspink HJ,Perkovic V,de Zeeuw D.Renal and cardio-protective effects of direct renin inhibition:a systematic literature review.J Hypertens,2009,27:2321-2331.

同被引文献30

  • 1Dzau V. The cardiovascular continuum and renin-angiotensin- aldosterone system blockade. J Hypertens Suppl, 2005,23: S9-17.
  • 2Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases : do we need a more comprehensive strategy? Rev Cardiovasc Med, 2006,7: 45-54.
  • 3Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Phannacol, 2009,78 : 933-940.
  • 4Fogari R, Zoppi A. New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag, 2010, 6: 869-882.
  • 5Masson S, Solomon S, Angelici L, et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail, 2010, 16: 964- 970.
  • 6Kappert K, Unger T, Kintscher U. Aliskiren hemifumarate. Dtsch Med Wochenschr, 2008,133 : 1308-1312.
  • 7Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coil Cardiol, 2007, 49 : 1157-1163.
  • 8Batenburg WW, de Bruin 1LI, van Gool JM, et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2008, 28: 1151-1157.
  • 9Epstein BJ. Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag, 2010, 6 : 711-722.
  • 10Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension : a 6-month, randomized, double-blind trial. J Hypertens, 2008, 26: 589-599.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部